Cost-effectiveness of different interferon beta products for relapsing-remitting and secondary progressive multiple sclerosis: Decision analysis based on long-term clinical data and switchable treatments

BACKGROUND: Multiple sclerosis (MS) is a highly debilitating immune mediated disorder and the second most common cause of neurological disability in young and middle-aged adults. Iran is amongst high MS prevalence countries (50/100,000). Economic burden of MS is a topic of important deliberation in...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Nikfar, Shekoufeh, Kebriaeezadeh, Abbas, Dinarvand, Rassoul, Abdollahi, Mohammad, Sahraian, Mohammad-Ali, Henry, David, Akbari Sari, Ali
Format: Artigo
Idioma:Inglês
Publicat: BioMed Central 2013
Matèries:
Research Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC3698128/
https://ncbi.nlm.nih.gov/pubmed/23800250
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/2008-2231-21-50
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars